PROTOCOL NRG-CC004– Adverse Event Reporting and PRO Compliance

Adverse event reporting on NRG-CC004 is a very important part of the study. In order to move to a phase III, the bupropion dose with improvement over placebo in sexual desire needs to have no reported grade 4+ SAE’s attributable to treatment and ≤ 20% of patients on the bupropion arm of interest would not have stopped protocol treatment based on AE’s. Therefore, it is crucial that adverse event data is reported, including for women who stop protocol treatment early due to toxicity. NRG Oncology will contact sites regarding delinquency in adverse event reporting. Collection of patient reported outcomes is an integral part of this study and should also be completed as close to the protocol-specified time as possible.

 

View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.
This message was sent from NRG-Broadcasts@NRGOncology.org to NRG-Broadcasts@NRGOncology.org
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address | Forward Email | Report Abuse